论文部分内容阅读
艾司洛尔(Esmolol)是一新型无内源性拟交感神经活性的心脏选择性β_1受体阻滞剂,半衰期仅9分钟。本文探讨在接受常规抗心绞痛药物治疗的不稳定型心绞痛患者,它的血液动力学和抗心肌缺血的效应。方法 113例不稳定性型心绞痛患者被随机分为艾司洛尔治疗组(59例)和安慰剂组(54例)。患者入选前3个月内心绞痛逐渐加重,或有静息性心绞痛;入院前48小时内
Esmolol is a novel cardioselective β-1 blocker with no endogenous sympathomimetic activity with a half-life of only 9 minutes. This article investigates the effects of hemodynamics and anti-myocardial ischemia on patients with unstable angina who have undergone conventional anti-anginal drug therapy. Methods A total of 113 unstable angina patients were randomly divided into esmolol group (n = 59) and placebo group (n = 54). Patients with angina gradually aggravate within the first 3 months, or have resting angina; within 48 hours before admission